Morepen Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−0.3%+8.4%
EBITDA−27.8%+16.5%
Net Income−19.6%+34.9%
EPS (adj.)−19.6%+34.9%
Total Assets+8.9%+20.4%
Total Equity+5.1%+18.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MOREPENLAB₹125.58

Morepen Laboratories Limited

· Pharma & Health
₹ CrorePeersIOLCPINNOVACAPFDCORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹6,881 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-0.3+8.4
EBITDA-27.8+16.5
Net Income-19.6+34.9
EPS (adj.)-19.6+34.9
Total Assets+8.9+20.4
Total Equity+5.1+18.3
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.